Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $390
Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE: WST ) with a Overweight and raises the price target from $350 to $390.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.